The present disclosure provides an antimicrobial alginate fiber, a method for manufacturing an antimicrobial alginate fiber dressing thereof, and an application thereof. When the cationic polymer polyhexamethylene guanide salt is mixed with the anionic polymer alginate, the antimicrobial activity of the guanide salt is quickly passivated. The present disclosure achieves a lower content of polyhexamethylene guanide salt in an alginate dressing with good long-term antimicrobial activities. The polyhexamethylene guanide salt has a low dissolution rate, and significantly reduces a potential risk of carcinogenicity, mutagenicity and reproductive toxicity.

The present disclosure relates to methods for producing tissue matrix products with active agents to achieve localized distribution and controlled active agent release. The method can include inserting a carrier element comprising a biodegradable material and active agent into surface features of a tissue matrix product. Also provided are tissue matrix products made using the disclosed methods.

Systems, methods, and articles for providing an antimicrobial composition to the proximal elements of a trans-dermal catheter and into the lumen of the transdermal catheter are disclosed. In an embodiment, an antimicrobial composition on surface a cap element transfers antimicrobial to the proximal end of the transdermal catheter. The system comprises an elongate member configured for insertion into a lumen of a catheter, the elongate member containing an antimicrobial.

A biocidally active polymer composition formed from an oligomeric or polymeric additive and a thermoplastic polyurethane polymer is disclosed. The biocidally active polymer may further include a non-fouling and/or non-thrombogenic polymer. The biocidally active polymer provides biocidally active properties, and may also provide non-fouling and/or non-thrombogenic properties. The composition is particularly useful in articles and materials for medical applications.

The subject matter of the present invention is, according to a first aspect, a dressing comprising an interface layer, characterised in that said interface layer comprises a weave coated with an elastomeric matrix comprising metformin, the salts and the complexes thereof. The subject matter of the invention is also a dressing comprising metformin, characterised in that the percentage of metformin released after 72 hours is between 40 and 100% of the quantity of metformin inserted in the dressing. Moreover, the subject matter of the invention is a method for producing said dressing as well as the use thereof for healing a wound.

Antimicrobial laminates of the invention include at least one adhesive layer; a backing outwardly exposed on a first side of the adhesive layer; and, optionally, a release liner outwardly exposed on a second side of the adhesive layer opposite from the first side of the adhesive layer. At least one of the at least one adhesive layer and the backing includes an antimicrobially effective amount of substantially pure chlorhexidine.

Compositions containing chlorhexidine gluconate solubilized in hydrophobic vehicles are described. Resin systems containing such chlorhexidine gluconate compositions, including adhesives and articles incorporating such resin systems, including medical articles such as drapes are also described.

A full-surround contact antimicrobial dressing is disclosed. The dressing includes a transparent body that covers a skin insertion site through which a catheter assembly passes for disposal within the body of a patient. The transparency of the dressing body enables inspection of the skin insertion site. In one embodiment, therefore, an antimicrobial full-surround contact dressing for use with a medical device inserted into a skin surface of a patient via a skin insertion site is disclosed and comprises a transparent flat body, an antimicrobial adhesive substance disposed on a bottom surface of the body, and a slit defined in the body. The slit is configured to enable the body to be placed fully around a perimeter of the medical device on the skin surface at the skin insertion site such that the bottom surface of the body fully surrounds and contacts the skin insertion site.

An improvement to the effectiveness or take of skin grafts or tissue replacements used to treat wounds is provided. A therapeutic composition comprising recombinant human platelet-derived growth factor BB homodimer (rhPDGF-BB) and a porous biocompatible carrier is first applied to the wound surface, followed by applying a skin substitute or tissue replacements composition.

Described is a wound care product having a backing layer and an adhesive layer having a skin-facing surface, wherein at least a portion of the skin-facing surface of the adhesive layer has an antimicrobial coating.